Click Holdings Limited (NASDAQ:CLIK) Short Interest Update

Click Holdings Limited (NASDAQ:CLIK) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 1,939 shares, a decrease of 94.9% from the June 30th total of 37,691 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 56,286 shares, the days-to-cover ratio is presently 0.0 days.

Click Trading Up 1.9%

NASDAQ CLIK traded up $0.03 during mid-day trading on Friday, hitting $1.63. The company’s stock had a trading volume of 45,626 shares, compared to its average volume of 373,797. Click has a 52-week low of $1.32 and a 52-week high of $14.40. The stock’s fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $2.70.

Click (NASDAQ:CLIK) last released its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $3.79 million for the quarter.

Analyst Ratings Changes

CLIK has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Click to a “hold” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Trading of Click

A hedge fund recently bought a new position in Click stock. Renaissance Technologies LLC purchased a new stake in Click Holdings Limited (NASDAQ:CLIK) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click at the end of the most recent quarter.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.